Ciprofloxacin/fluocinolone acetonide

Drug Profile

Ciprofloxacin/fluocinolone acetonide

Alternative Names: Cetraxal Comp; Cetraxal Plus; DF277/DF289; DF289/DF277; Duoxal; Fluocinolone acetonide/ciprofloxacin; Infalin Duo; Otixal; Otixal®; Otospon; Otovel; OTOVEL; Ultramicina Plus

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator SALVAT
  • Developer Arbor Pharmaceuticals; Pediapharm; SALVAT
  • Class Anti-inflammatories; Antibacterials; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Pregnadienes; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Phospholipase A2 inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 18 May 2017 Launched for Otitis media (In children, In infants) in Canada (Otic)
  • 12 Dec 2016 Registered for Otitis media (In children, In infants) in Canada (Otic)
  • 29 Aug 2016 Ciprofloxacin/fluocinolone licensed to Arbor Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top